Tissue thromboplastin induces rapid inhibition of fibrinolysis in rabbits

Fibrinolysis

Volumn 10, Issue 3, 1996, Pages 143-149

  Filtenborg Tvedskov, T ^a   Vad, H ^a   Albrechtsen, O K ^a   Gram, J ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ESBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 12; PLASMINOGEN; PLASMINOGEN ACTIVATOR; THROMBOPLASTIN; UROKINASE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOSIS;

EID: 0029984923     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80025-7     Document Type: Article

References (29)

1. Astrup T, Jespersen J. Thrombosis, diseminated intravascular coagulation, and the dynamic haemostatic balance. Aspects of prophylaxis and treatment. Int Angiol 1984; 3: 331-42.
2. Wardle E N. Coagulation problems in intensive care patients. Care Grit Il 193; 9: 246-9.
3. Bick R L. Disseminated intravascular coagulation: objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response. Clin Appl Thromb/Haemost 1995; 1: 3-23.
4. Suffredini A F, Harpel P C, Parrillo J E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
5. Levi M, ten Gate H, van der Poll T, van Devanters J H. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 210: 975-9.
6. Thijs L G, de Boer J P, de Groot M C M, Hack C E. Coagulation disorders in septic shock. Int Care Med 1993; 19: S8-S15.
7. Albrechtsen O K, Brakman P, Astrup T. The debrination syndrome in rabbits following infusion of tissue thromboplastin in the jugular vein. Thromb Diath Haemorrh 1970; 24: 113-28.
8. Marble G A, Griffith M T. Tissue thromboplastin induced reversible DIG and heparin-enhanced inhibitors in dogs. Thromb Haemost 1986; 55: 78-85.
9. Saldeen T. The disappearance of fibrin from the pulmonary vessels in experimental fat embolism. Thromb Diath Haemorrh 1969; 22: 360-71.
10. Jespersen J, Sidelmann J. A study of the conditions and accuracy of thrombin time assay of fibrinogen. Acta Haematol 1982; 67: 2-7.
11. Gram J, Jespersen J. A functional plasminogen assay utilizing the potentiating effect of fibrinogen to correct for the overestimation of plasminogen in pathological plasma samples. Thromb Haemost 1985; 53: 255-9.
12. 2-macroglobulin during the normal menstrual cycle and in women on oral contraceptives low in oestrogen. Thromb Haemost 1983; 50: 581-5.
13. Jespersen J, Astrup T. A study of the fibrin plate assay of fibrinolytic agents. Optimal conditions, reproducibility and precision. Haemostasis 1983; 13: 301-15.
14. Gram J, Jespersen J, Astrup T. A delaying influence of cryoglobulins in the assessment of euglobulin fibrinolytic activity. Thromb Res 1986; 41: 781-9.
15. Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemost 1979; 41: 365-83.
16. Gram J, Jespersen J. A simplified estimation of tissue plasminogen activator (t-PA) inhibition in human plasma. Fibrinolysis 1987; 1: 33-7.
17. Kluft C, Wijngaards G, Jie A F H. Intrinsic plasma fibrinolysis: involvement of urokinase-related activity in the factor XII-independent plasminogen proactivator pathway. J Lab Clin Med 1984; 131: 408-19.
18. Munkvad S, Jespersen J, Gram J, Kluft C. Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infaraction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study. J Am Coll Cardiol 1991; 17: 957-62
19. Munkvad S, Jespersen J, Gram J, Kluft C. Depression of factor XII-dependent fibrinolytic activity characterizes patients with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy. J Am Coll Cardiol 1991; 18: 454-8.
20. Gurewich V, Pannell R. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: a relevance of the findings to the interpretation of fibrin-binding experiments. Blood 1987; 69: 769-72.
21. Gelehrter T D, Sznycer-Laszuk R. Thrombin induction of plasminogen activator inhibitor in cultured human endothelial cells. J Clin Invest 1986; 77: 165-9.
22. Hinsberg V W M, Sprengers E D, Kooistra T. Effect of thrombin on production of plasminogen activators and PA-inhibitor 1 by human foreskin microvascular endotheial cells. Thromb Haemost 1987; 57: 148-57.
23. Sprengers E D, Akkerman J W N, Jansen B G. Blood platelet plasminogen activator: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost 1986; 55: 325-9.
24. Sprengers E D, Kluft C. Plasminogen activator inhibitors. Blood 1987 1987; 69: 381-7.
25. Booth N A, Simpson A J, Croll A, Bennett B, MacGregor I R. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-33.
26. Booth N A, Croll A, Bennett B. The activity of plasminogen activator inhibitor-1 (PAI-1) of human platelet. Fibrinolysis 1990; 4 (suppl 2): 138-40.
27. Lambers J W J, Cammenga M, König B W, Mertens K, Pannekoek H, Van Mourik J A. Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids. J Biol Chem 1987; 262: 17492-6.
28. 2-antiplasmin from human platelets. Blood 1981; 58: 1069-73.
29. Leung L L K, Harpel P C, Nachman R L, Rabellino E M. Histidinerich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood 1983; 62: 1016-21.